SCHEMBL6947129

SCHEMBL6947129

CC(C)OC(=N)Cc1cn(C)c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.53
KDM4E B2RXH2 3/20 0.52
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HTR2A P28223 1/20 0.48
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
PTPN5 P54829 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
IDO1 P14902 1/20 0.42
GAA P10253 2/20 0.42
CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6947124 0.99 GPR84 (0.51) GPR84KDM4EMAPTLMNAALDH1A1
SCHEMBL23084313 0.83 KDM4E (0.59) GPR84KDM4EMAPTLMNAALDH1A1
SCHEMBL7590800 0.81 PTGER1 (0.39) KDM4EMAPTLMNAALDH1A1MEN1
SCHEMBL7593245 0.81 KDM4E (0.38) GPR84KDM4EMAPTLMNAALDH1A1
Hydrochloric Acid SCHEMBL7507527 0.81 KDM4E (0.38) KDM4EMAPTLMNAALDH1A1GAA
Hydrochloric Acid SCHEMBL7508645 0.81 MAPT (0.36) GPR84KDM4EMAPTLMNAALDH1A1
SCHEMBL7593453 0.81 MEN1 (0.39) GPR84KDM4EMAPTLMNAALDH1A1
Hydrochloric Acid SCHEMBL7988085 0.80 PTGER1 (0.38) KDM4EMAPTLMNAALDH1A1MEN1
Hydrochloric Acid SCHEMBL7990620 0.80 KDM4E (0.37) GPR84KDM4EMAPTLMNAALDH1A1
Hydrochloric Acid SCHEMBL7990631 0.80 MEN1 (0.39) GPR84KDM4EMAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069377-A1 DEUTERIUM-ENRICHED ENZASTAURIN PROTIA, LLC (US) 2009-03-12 US disclosed
US-20090069377-A1 DEUTERIUM-ENRICHED ENZASTAURIN PROTIA, LLC (US) 2009-03-12 US disclosed
EP-0915872-B1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION HOFFMANN LA ROCHE (CH) 2003-05-14 EP disclosed
EP-1242409-A2 SUBSTITUTED BISINDOLYLMALEIMIDES F. HOFFMANN-LA ROCHE AG (CH) 2002-09-25 EP disclosed
WO-2001046178-A2 SUBSTITUIERTE BISINDOLYMALEIMIDE F. HOFFMANN-LA ROCHE AG (CH) 2001-06-28 WO disclosed
EP-0915872-A1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION F. HOFFMANN-LA ROCHE AG (CH) 1999-05-19 EP disclosed
WO-1998004552-A1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION F. HOFFMANN-LA ROCHE AG (CH) 1998-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069377-A1 DEUTERIUM-ENRICHED ENZASTAURIN TMPRSS15, NEK5, HDHD5 GPR84 2603/4885KDM4E 1674/4885MAPT 3779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.